ESMO Guidance for Reporting Oncology real-World evidence (GROW)Luís Castelo-Branco, Miriam Koopman, Arndt Vogel et al.|Annals of Oncology|2023Cited by 209
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Domenica Lorusso et al.|The Lancet Oncology|2021Cited by 148
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancerMaría Pilar Carrera-González, Carla Ripamonti, Giuseppe Curigliano et al.|ESMO Open|2024Cited by 54
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewFederica Miglietta, Valentina Guarneri, Alessandra Fabi et al.|Cancer Treatment Reviews|2023Cited by 13